Development for high-accuracy in vitro assay of vascular endothelial growth factor using nanomagnetically labeled immunoassay

C. C. Yang, K. W. Huang, S. Y. Yang, H. H. Chen, T. C. Chen, C. S. Ho, S. F. Chang, J. J. Chieh, H. E. Horng, C. Y. Hong, H. C. Yang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nanomagnetically labeled immunoassays have been demonstrated to be promisingly applied in clinical diagnosis. In this work, by using antibody-functionalized magnetic nanoparticles and a high-temperature superconducting quantum interference device ac magnetosusceptometer, the assay properties for vascular endothelial growth factor (VEGF) in serum are investigated. By utilizing the assay method so-called immunomagnetic reduction, the properties of assaying VEGF are explored. In addition, the VEGF concentrations in serum samples of normal people and patients with either colorectal or hepatocellular cancer are detected. The experimental results show that the low-detection limit for assaying VEGF is 10 pg/mL, which is much lower than the clinical cut-off VEGF concentration of 50 pg/mL for diagnosing malignancy. Besides, there are no significant interference effects on assaying VEGF from hemoglobin, conjugated bilirubin, and triglyceride. The VEGF concentrations in serum samples donated by normal people and patients with hepatocellular carcinoma or colorectal cancer are detected. A clear difference in VEGF concentrations between these two groups is found. These results reveal the feasibility of applying nanomagnetically labeled immunoassay to clinics.

Original languageEnglish
Article number695276
JournalJournal of Nanomaterials
Volume2013
DOIs
Publication statusPublished - 2013 Oct 31

Fingerprint

Vascular Endothelial Growth Factor A
Assays
Intercellular Signaling Peptides and Proteins
Hemoglobin
SQUIDs
Bilirubin
Antibodies
Hemoglobins
Triglycerides
Nanoparticles

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Development for high-accuracy in vitro assay of vascular endothelial growth factor using nanomagnetically labeled immunoassay. / Yang, C. C.; Huang, K. W.; Yang, S. Y.; Chen, H. H.; Chen, T. C.; Ho, C. S.; Chang, S. F.; Chieh, J. J.; Horng, H. E.; Hong, C. Y.; Yang, H. C.

In: Journal of Nanomaterials, Vol. 2013, 695276, 31.10.2013.

Research output: Contribution to journalArticle

Yang, C. C. ; Huang, K. W. ; Yang, S. Y. ; Chen, H. H. ; Chen, T. C. ; Ho, C. S. ; Chang, S. F. ; Chieh, J. J. ; Horng, H. E. ; Hong, C. Y. ; Yang, H. C. / Development for high-accuracy in vitro assay of vascular endothelial growth factor using nanomagnetically labeled immunoassay. In: Journal of Nanomaterials. 2013 ; Vol. 2013.
@article{f2151f2ef77948ff9b80c2af3040b45e,
title = "Development for high-accuracy in vitro assay of vascular endothelial growth factor using nanomagnetically labeled immunoassay",
abstract = "Nanomagnetically labeled immunoassays have been demonstrated to be promisingly applied in clinical diagnosis. In this work, by using antibody-functionalized magnetic nanoparticles and a high-temperature superconducting quantum interference device ac magnetosusceptometer, the assay properties for vascular endothelial growth factor (VEGF) in serum are investigated. By utilizing the assay method so-called immunomagnetic reduction, the properties of assaying VEGF are explored. In addition, the VEGF concentrations in serum samples of normal people and patients with either colorectal or hepatocellular cancer are detected. The experimental results show that the low-detection limit for assaying VEGF is 10 pg/mL, which is much lower than the clinical cut-off VEGF concentration of 50 pg/mL for diagnosing malignancy. Besides, there are no significant interference effects on assaying VEGF from hemoglobin, conjugated bilirubin, and triglyceride. The VEGF concentrations in serum samples donated by normal people and patients with hepatocellular carcinoma or colorectal cancer are detected. A clear difference in VEGF concentrations between these two groups is found. These results reveal the feasibility of applying nanomagnetically labeled immunoassay to clinics.",
author = "Yang, {C. C.} and Huang, {K. W.} and Yang, {S. Y.} and Chen, {H. H.} and Chen, {T. C.} and Ho, {C. S.} and Chang, {S. F.} and Chieh, {J. J.} and Horng, {H. E.} and Hong, {C. Y.} and Yang, {H. C.}",
year = "2013",
month = "10",
day = "31",
doi = "10.1155/2013/695276",
language = "English",
volume = "2013",
journal = "Journal of Nanomaterials",
issn = "1687-4110",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Development for high-accuracy in vitro assay of vascular endothelial growth factor using nanomagnetically labeled immunoassay

AU - Yang, C. C.

AU - Huang, K. W.

AU - Yang, S. Y.

AU - Chen, H. H.

AU - Chen, T. C.

AU - Ho, C. S.

AU - Chang, S. F.

AU - Chieh, J. J.

AU - Horng, H. E.

AU - Hong, C. Y.

AU - Yang, H. C.

PY - 2013/10/31

Y1 - 2013/10/31

N2 - Nanomagnetically labeled immunoassays have been demonstrated to be promisingly applied in clinical diagnosis. In this work, by using antibody-functionalized magnetic nanoparticles and a high-temperature superconducting quantum interference device ac magnetosusceptometer, the assay properties for vascular endothelial growth factor (VEGF) in serum are investigated. By utilizing the assay method so-called immunomagnetic reduction, the properties of assaying VEGF are explored. In addition, the VEGF concentrations in serum samples of normal people and patients with either colorectal or hepatocellular cancer are detected. The experimental results show that the low-detection limit for assaying VEGF is 10 pg/mL, which is much lower than the clinical cut-off VEGF concentration of 50 pg/mL for diagnosing malignancy. Besides, there are no significant interference effects on assaying VEGF from hemoglobin, conjugated bilirubin, and triglyceride. The VEGF concentrations in serum samples donated by normal people and patients with hepatocellular carcinoma or colorectal cancer are detected. A clear difference in VEGF concentrations between these two groups is found. These results reveal the feasibility of applying nanomagnetically labeled immunoassay to clinics.

AB - Nanomagnetically labeled immunoassays have been demonstrated to be promisingly applied in clinical diagnosis. In this work, by using antibody-functionalized magnetic nanoparticles and a high-temperature superconducting quantum interference device ac magnetosusceptometer, the assay properties for vascular endothelial growth factor (VEGF) in serum are investigated. By utilizing the assay method so-called immunomagnetic reduction, the properties of assaying VEGF are explored. In addition, the VEGF concentrations in serum samples of normal people and patients with either colorectal or hepatocellular cancer are detected. The experimental results show that the low-detection limit for assaying VEGF is 10 pg/mL, which is much lower than the clinical cut-off VEGF concentration of 50 pg/mL for diagnosing malignancy. Besides, there are no significant interference effects on assaying VEGF from hemoglobin, conjugated bilirubin, and triglyceride. The VEGF concentrations in serum samples donated by normal people and patients with hepatocellular carcinoma or colorectal cancer are detected. A clear difference in VEGF concentrations between these two groups is found. These results reveal the feasibility of applying nanomagnetically labeled immunoassay to clinics.

UR - http://www.scopus.com/inward/record.url?scp=84886452857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886452857&partnerID=8YFLogxK

U2 - 10.1155/2013/695276

DO - 10.1155/2013/695276

M3 - Article

AN - SCOPUS:84886452857

VL - 2013

JO - Journal of Nanomaterials

JF - Journal of Nanomaterials

SN - 1687-4110

M1 - 695276

ER -